[1]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327-330.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(06):327-330.[doi:10.13798/j.issn.1009-153X.2016.06.003]
点击复制

173例胶质瘤预后的影响因素分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2016年06期
页码:
327-330
栏目:
论著
出版日期:
2016-06-25

文章信息/Info

Title:
Prognostic factors for gliomas: analysis of 173 cases
文章编号:
1009-153X（2016）06-0327-04
作者:
李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平
510060 广州，中山大学肿瘤防治中心神经外科（李剑峰、陈银生、赛　克、张湘衡、柯　超、杨群英、牟永告、陈忠平）；515031 广东汕头，中山大学附属汕头医院神经外科（李剑峰、许海雄）
Author(s):
LI Jian-feng1; 2;  CHEN Yin-sheng1;  SAI Ke1;  ZHANG Xiang-heng1;  KE Chao1;  YANG Qun-ying1;  MOU Yong-gao1;  XU Hai-xiong2;  CHEN Zhong-ping1.
1. Department of Neurosurgery, Cancer Medicine Center, Sun Yat-sen University, Guangzhou 515031, China; 2. Department of Neurosurgery, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou 515031, China
关键词:
胶质瘤; 预后; 影响因素
Keywords:
Glioma;  Treatment;  Prognosis;  Prognostic factor
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2016.06.003
文献标志码:
A
摘要:
目的 探讨影响胶质瘤预后的相关因素。方法 对2000年1月至2009年12月在中山大学肿瘤防治中心首次手术病理确诊为胶质瘤的临床资料进行回顾性分析，并排除因非肿瘤因素死亡患者，采用Kaplan-Meier法进行生存率估计及Cox比例风险回归模型进行预后多因素分析。结果 本组纳入胶质瘤173例，其中WHO Ⅰ级10例，Ⅱ级61例，Ⅲ级53例，Ⅳ级49例；98例术后接受放疗[高级别胶质瘤（WHOⅢ~Ⅳ级）61例，低级别胶质瘤（WHO Ⅰ~Ⅱ级）37例]；60例术后接受化疗（高级别胶质瘤46例，低级别胶质瘤14例）。本组患者1、3、5年总体生存率分别为74.0%、42.2%、32.4%；WHO Ⅰ、Ⅱ、Ⅲ、Ⅳ级的 5年生存率分别为80.0%、52.5%、24.5%、6.1%。分层分析显示术后辅助放化疗显著影响高级别胶质瘤生存率（P <0.05）。Cox比例风险回归模型分析结果 显示，年龄>40岁（RR=1.603；P=0.019）、WHO Ⅲ~Ⅳ分级（RR=2.311；P <0.001）、肿瘤未全切（RR=2.108；P <0.001）、术后未放疗（RR=1.652；P=0.008）是影响胶质瘤总体生存率的独立危险因素。结论 本组病例的分析结果 提示，发病年龄≤40岁、WHO级别低、肿瘤全切的胶质瘤患者预后好；术后进行放疗可以提高胶质瘤的疗效。
Abstract:
Objective To analyze the prognostic factors for patietns with gliomas. Methods The clinical data of 173 patients with pathologically confirmed gliomas at Sun Yat-sen University Cancer Center from January of 2000 to December of 2009 were analyzed retrospectively. Survival was estimated by Kaplan-Meier analysis. The univariateand multivariate analysis of the factors related to the prognosis was performed. Results Among 173 patients, 10 (5.8%) were diagnosed with WHO grade Ⅰ gliomas, 61 (35.3%) with grade Ⅱgliomas, 53 (30.6%) with grade Ⅲ gliomas and 49 (28.3%) with glioblasto mamultiforme, respectively. Of 98 patients who received postoperative radiotherapy, 61 had high-grade gliomas (WHO grades Ⅲ and Ⅳ) and 37 low-grade gliomas (WHO grades Ⅰ and Ⅱ), respectively. Of 60 patients who received adjuvant chemotherapy, 46 had high-grade gliomas and 14 low-grade gliomas, respectively. The 1-, 3- and 5-year overall survival of 173 patients was 74.0%, 42.2% and 32.4%, respectively. The 5-year overall survival of the patients with gliomas of WHO grade Ⅰ, Ⅱ, Ⅲ and Ⅳ was 80.0%, 52.5%, 24.5% and 6.1%, respectively. The univariate analysis showed that gender, age, preoperative seizure, histological grade, tumor location (supratentorial or subtentorial) and extent of resection (total or partial) were factors related to the prognosis for patients with gliomas. The stratified analysis by log-rank test revealed that adjuvant radiotherapy was a prognostic factor for patients with high-grade gliomas but not for those with low-grade gliomas. Breslow test indicated that adjuvant chemotherapy was a prognostic factor for patients with high-grade gliomas. The multivariate analysis showed that the prognostic factors included age (≤40 or >40 years), histological grade, the extent of resection and post-operative radiotherapy for glioma patients. Conclusions The Results showed that the age ≤40 years, gliomas of lower grade and total resection of tumor were associated with improved overall survival in the patients with gliomas. The patients with high-grade gliomas and the patients with a certain subgroup of low-grade gliomas may benefit from post-operative radiotherapy and adjuvant chemotherapy.

参考文献/References:

[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011 [J]. Neuro Oncol, 2014, 16(Suppl 4): iv1-63.
[2] 牟永告，陈明振，陈忠平，等. 脑胶质瘤的显微手术治疗— 附183例报告[J]. 癌症，2004，23（11）：1317-1321.
[3] Hou LC, Veeravagu A, Hsu AR, et al. Recurrent glioblas- toma multiforme: a review of natural history and manage- ment options [J]. Neurosurg Focus, 2006, 20: E5.
[4] Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemisphe- ric gliomas [J]. J Clin Oncol, 2008, 26: 1338-1345.
[5] Barker FG, 2nd, Chang SM, Larson DA, et al. Age and ra- diation response in glioblastoma multiforme [J]. Neurosur- gery, 2001, 49: 1288-1288.
[6] van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial [J]. Lancet, 2005, 366: 985-990.
[7] Louis BN, Mark RG, Ian P, et al. Version 1.2015 of the NCCN guidelines for central nervous system cancers [M]. J Natl Compr Canc Netw, 2015.
[8] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblas- toma [J]. N Engl J Med, 2005, 352: 987-996.
[9] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radio- therapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Oncol, 2009, 10: 459-466.
[10] Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincri- stine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 [J]. J Clin Oncol, 2012, 30: 3065-3070.
[11] Quinn JA, Reardon DA, Friedman AH, et al. Phase Ⅱtrial of temozolomide in patients with progressive low-grade glioma [J]. J Clin Oncol, 2003, 21: 646-651.
[12] Pouratian N, Gasco J, Sherman JH, et al. Toxicity and effi- cacy of protracted low dose temozolomide for the treatment of low grade gliomas [J]. J Neurooncol, 2007, 82: 281-288

相似文献/References:

[1]于　涛　黄正通　王振宇.椎管内脊膜囊肿的临床特征和治疗方法[J].中国临床神经外科杂志,2015,(11):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
　YU Tao,HUANG Zheng-tong,WANG Zhen-yu.Clinical features and treatment of intraspinal arachnoid cysts[J].,2015,(06):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
[2]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(06):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[3]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[4]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[7]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[8]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[9]周　量　刘　丛　张昌伟.早期栓塞术治疗动脉瘤性蛛网膜下腔出血的疗效[J].中国临床神经外科杂志,2016,(07):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
　ZHOU Liang,LIU Cong,ZHANG Chang-wei..Curative effect of early endovascular embolization on patients with ruptured intracranial aneurysms[J].,2016,(06):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
[10]陈吉钢　张丹枫　魏嘉良　邹　伟　侯立军.创伤性眶上裂综合征的治疗陈吉钢[J].中国临床神经外科杂志,2016,(04):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
　CHEN Ji-gang,ZHANG Dan-feng,WEI Jiang-liang,et al.Management of traumatic superior orbital fissure syndrome (report of 22 cases)[J].,2016,(06):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
[11]任　勇,何　威,齐曼丽,等.TEM8在人脑胶质瘤中的表达及其意义[J].中国临床神经外科杂志,2016,(12):768.[doi:10.13798/j.issn.1009-153X.2016.12.012]
　REN Yong,HE Wei,QI Man-li,et al.Expression of TEM8 in human gliomas and its clinical meaning[J].,2016,(06):768.[doi:10.13798/j.issn.1009-153X.2016.12.012]
[12]孙连杰,麦麦提依明·托合提,杨小朋.与胶质瘤诊断及预后相关的分子标记物的研究进展[J].中国临床神经外科杂志,2018,(09):633.[doi:10.13798/j.issn.1009-153X.2018.09.022]
[13]穆寅东　赵天书　谢　清.脑胶质瘤SOX7基因的甲基化状态及临床意义[J].中国临床神经外科杂志,2019,(02):90.[doi:10.13798/j.issn.1009-153X.2019.02.009]
　MU Yin-dong,ZHAO Tian-shu,XIE Qing..Methylation state of SOX9 in human glioma and its clinical meanings[J].,2019,(06):90.[doi:10.13798/j.issn.1009-153X.2019.02.009]
[14]孙宇婷　冯钰珉　戴科芳　郝进敏.Ddx5 和 Ddx17在人脑胶质瘤中的表达及其与病人生存期的关系[J].中国临床神经外科杂志,2020,(06):362.[doi:10.13798/j.issn.1009-153X.2020.06.008]
　SUN Yu-ting,FENG Yu-min,DAI ke-fang,et al.Relationship between expression levels of Ddx5 and Ddx17 in glioma tissues and survival time of patients with giloma[J].,2020,(06):362.[doi:10.13798/j.issn.1009-153X.2020.06.008]
[15]田　伟　李　峰　张　彬.STRAP在人脑胶质瘤组织中的表达及临床意义[J].中国临床神经外科杂志,2020,(08):510.[doi:10.13798/j.issn.1009-153X.2020.08.005]
　TIAN Wei,LI Feng,ZHANG Bin..Expression of serine threonine kinase receptor associated protein in human glioma tissues and its clinical significance[J].,2020,(06):510.[doi:10.13798/j.issn.1009-153X.2020.08.005]
[16]崔　敬　佟建洲.HOXC10在人脑胶质瘤中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2020,(08):513.[doi:10.13798/j.issn.1009-153X.2020.08.006]
　CUI Jing,TONG Jian-zhou..Expression of HOXC10 in human glioma tissue and its relationship with prognosis of patients with glioma[J].,2020,(06):513.[doi:10.13798/j.issn.1009-153X.2020.08.006]
[17]徐敬轩　杨　岩　张　勖　郭　正　喀斯木　栾新平.环状RNA circ-0014359在胶质瘤组织中的表达及意义[J].中国临床神经外科杂志,2020,(10):680.[doi:10.13798/j.issn.1009-153X.2020.10.007]
　XU Jing-xuan,YANG Yan,ZHANG Xu,et al.Expression of circRNA circ-0014359 in human glioma tissues and its clinical significance[J].,2020,(06):680.[doi:10.13798/j.issn.1009-153X.2020.10.007]
[18]张志银　李　泽　李　华　张良君　杨　春.ERH在人脑胶质瘤中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2020,(11):753.[doi:doi:10.13798/j.issn.1009-153X.2020.11.006]
　ZHANG Zhi-yin,LI Ze,LI Hua,et al.Expression of enhancer of rudimentary homolog in glioma tissues and its relationship with glioma patients’ prognoses[J].,2020,(06):753.[doi:doi:10.13798/j.issn.1009-153X.2020.11.006]
[19]孙青青　任洪波　牛国栋.lncRNA SNHG16在人脑胶质瘤组织中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2020,(12):831.[doi:10.13798/j.issn.1009-153X.2020.12.005]
　SUN Qing-qing,REN Hong-bo,NIU Guo-dong..Expression of lncRNA SNHG16 in human glioma tissues and its relationship with prognosis of glioma patients[J].,2020,(06):831.[doi:10.13798/j.issn.1009-153X.2020.12.005]
[20]祝　斐　陈谦学.CHST2在胶质瘤中的表达及临床意义[J].中国临床神经外科杂志,2021,26(06):429.[doi:10.13798/j.issn.1009-153X.2021.06.008]
　ZHU fei,CHEN Qian-xue..Expression of CHST2 in human glioma tissues and its clinical significance based on bioinformatics analysis[J].,2021,26(06):429.[doi:10.13798/j.issn.1009-153X.2021.06.008]

备注/Memo

备注/Memo:

通讯作者：陈忠平，E-mail：chenzhp@sysucc.org.cn
更新日期/Last Update: 2016-06-20